Drug Trial Radar · NCT04444011
Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth
Last checked: Nov 19, 2026Latest source record: Jun 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Sep 30, 2020
Study completion Oct 15, 2020
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single-center, randomized, open-label, crossover study to evaluate the pharmacokinetic drug-drug interaction and safety of the quadruple therapy with Anaprazole 20mg/Amoxicilin 1000mg/Clarithromycin 500mg/Bismuth Potassium Citrate 0.6g in healthy Chinese male subjects.
Conditions
- Healthy Male Volunteers
Interventions
Anaprazole SodiumDrug
Anaprazole Sodium isthePPI inhibitor
AmoxicillinDrug
antibiotic
ClarithromycinDrug
antibiotic
BismuthDrug
Bismuth is to protect the gastric mucosa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Css,max of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
- Cohort 1: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
- Cohort 2: Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
- Cohort 2: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.